Drug Type Universal CAR-T |
Synonyms |
Target |
Mechanism NKG2D antagonists(NKG2-D type II integral membrane protein antagonists), Gene transference, T lymphocyte replacements |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization Leucid Bio Ltd.Startup |
Active Organization Leucid Bio Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hematologic Neoplasms | Preclinical | GB | Leucid Bio Ltd.Startup | 24 Apr 2022 |